

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5930216

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DAKO DENMARK APS	10/31/2019
RECEIVING PARTY DATA	
Name:	AGILENT TECHNOLOGIES, INC.
Street Address:	5301 STEVENS CREEK BLVD.
City:	SANTA CLARA
State/Country:	CALIFORNIA
Postal Code:	95051
PROPERTY NUMBERS Total: 11	
Property Type	Number
Patent Number:	8268964
Patent Number:	10336808
Patent Number:	10030065
Patent Number:	10369204
Application Number:	16440627
Application Number:	16015955
Application Number:	12680248
Application Number:	13055321
Application Number:	12919405
Application Number:	16455224
Application Number:	13122027
CORRESPONDENCE DATA	
Fax Number:	(408)884-2359
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	312-269-8023
Email:	dciecierski@nge.com
Correspondent Name:	MICHAEL B. HARLIN
Address Line 1:	TWO NORTH LASALLE STREET
Address Line 4:	CHICAGO, ILLINOIS 60602

ATTORNEY DOCKET NUMBER:	027644.6000
NAME OF SUBMITTER:	MICHAEL B. HARLIN
SIGNATURE:	/Michael B. Harlin/
DATE SIGNED:	01/27/2020
Total Attachments: 3 source=Confirmatory Assignment for US Immudex cases (signed)#page1.tif source=Confirmatory Assignment for US Immudex cases (signed)#page2.tif source=Confirmatory Assignment for US Immudex cases (signed)#page3.tif	

CONFIRMATORY PATENT ASSIGNMENT

This Patent Assignment is effective as of October 31, 2019 at 1:00 am Pacific Daylight Time ("Effective Date"), between Dako Denmark ApS, an entity organized and existing under the laws of Denmark, having a principal place of business at Produktionsvej 42, 2600 Glostrup, Denmark ("Assignor"), and Agilent Technologies, Inc., a Delaware corporation having a principal place of business at 5301 Stevens Creek Blvd, Santa Clara, California 95051, United States ("Assignee").

WHEREAS, pursuant to the Intangible Asset Transfer and License Agreement dated as of October 31, 2019 between Assignor and Assignee (the "Asset Transfer Agreement"), Assignor agreed to assign or cause to be assigned to Assignee all of Assignor's rights, title and interest in and to Assignor's patents and patent applications throughout the world.

1. Assignor hereby assigns and transfers to Assignee, its successors and assigns, the entire right, title and interest, including the right of priority in, to and under the applications for Letters Patent listed in Schedule A attached hereto and the invention(s) and improvement(s) set forth therein, and any and all continuations, continuations-in-part (CIPs), divisionals, and renewals of and substitutes for said application for said Letters Patent, and any and all Letters Patent of the United States and of countries foreign thereto which may be granted thereon or therefor; and any reissues, or reexaminations, or extensions of said Letters Patent ("the Assigned Patent Rights").

2. Assignor further grants, conveys and assigns to Assignee, on a worldwide basis, all of its rights, title, and interest in and to any and all proceeds, causes of action, rights to sue and bring claims, and all other rights of action or recovery for past, present, and future infringement or other violation of any of the Assigned Patent Rights, including rights to injunctive relief, damages, enhanced and exemplary damages, attorneys' fees, costs and expenses and all other legal and equitable remedies.

3. The parties understand and intend that this Patent Assignment is to be recorded in the United States Patent and Trademark Office and elsewhere around the world as appropriate.

4. Assignor agrees to execute all instruments and documents and do such additional acts as Assignee may deem necessary or desirable to effect, evidence, record, and perfect the assignment and recordation of the rights being assigned hereunder in this Patent Assignment. If Assignee is unable for any reason whatsoever to secure Assignor's signature to any document it is entitled to under this Patent Assignment, Assignor hereby irrevocably designates and appoints Assignee and its duly authorized officers and agents, as its attorneys-in-fact, with full power of substitution to act for and on their behalf and instead of Assignor to execute and file any such document or documents and to do all other lawfully permitted acts to further the purposes of the foregoing with the same legal force and effect as if executed by Assignor.


5. This Patent Assignment will inure to the benefit of and be binding upon Assignee and Assignor and their respective heirs, successors, and assigns.

6. This Patent Assignment may be executed in counterparts, each of which will be deemed an original, but all of which together constitute one and the same original. Any such signature page will be effective as a counterpart signature page hereto without regard to page, document or version numbers or other identifying information thereon, which are for convenience of reference only. This Patent Assignment may be executed by facsimile or .PDF signature, and a facsimile or .PDF signature will constitute an original signature for all purposes.

IN WITNESS WHEREOF, the undersigned have caused this Patent Assignment to be duly executed and delivered as of the Effective Date.

ASSIGNOR:

Dako Denmark ApS

By: 

Name: Simon Oestergaard

Title: GM and VP, Pathology

Date: 2020 JAN 27

Schedule A

Serial No.	Title	Country	Pat / Pub No.	Status
12619039	MHC Peptide Complexes and Uses Thereof in Infectious Diseases	US	8268964	Granted
13482472	MHC Peptide Complexes and Uses Thereof in Infectious Diseases	US	10336808	Granted
12644554	MHC Multimers, Methods For Their Generation, Labeling and Use	US	10030065	Granted
13122007	Molecular Vaccines For Infectious Disease	US	10369204	Granted
16440627	MHC Peptide Complexes and Uses Thereof in Infectious Diseases	US		Pending
16015955	MHC Multimers, Methods For Their Generation, Labeling and Use	US	20190085048A1	Pending
12680248	MHC Multimers In Tuberculosis Diagnostics, Vaccine and Therapeutics	US	20110236411A1	Pending
13055321	Combinatorial Analysis and Repair	US	20110212090A1	Pending
12919405	MHC Multimers in Borrelia Diagnostics and Disease	US		Pending
16455224	Molecular Vaccines for Infectious Disease	US	20190314471A1	Pending
13122027	MHC Multimers in Cancer Vaccines and Immune Monitoring	US	20110318380A1	Pending